- NewsCategory：
- All Company news Industry news
common105One result
-
1031
Gotham Therapeutics Establishes Advanced Onc¥↕∏ology Profiling Cascad≈↕γ↔e with ProQinase to Progress its Portfolio of Epπ"itranscriptomic Drug Candidates
Gotham Therapeutics Establishes Advanced Onc® ×ology Profiling Cascade with ProQinase to Pro>₽gress its Portfolio of÷↓ Epitranscriptomic Drug CandidatesWEDNESDAYγ♥, OCTOBER 30, 2019Gotham Therapeutics, a biot®®¶echnology company developing a novel drug class≠&ε targeting RNA-modifying™÷ proteins, and ProQinase, an early stage δdrug-discovery company, r♥$$ecently acquired by Malvern/PA-base₩φ★→d Reaction Biology Corp., today announced that ÷₩♣∏they have established an array of advan¥α¶ced biochemical and cellular assays to chara✘®cterize epitranscriptomic-directed compounds.“Esδ≠¥tablishing tailored target engagem¶±λπent, cell biology, phenotypic, and in-vivo ass☆©×ays to evaluate compoun €ds originating from our three most advaεσnced epitranscriptomic programs in para☆≠llel is a crucial next step to deve<±lop our broad pipeline to"↓∏wards the clinic,” said Dr. Gerhוard Müller, Chief Scientific ¶εε<Officer of Gotham Therapeutics. β᧓By pursuing the full range of the readα♦±er-writer-eraser continuum, we are able to fo∞€cus on targets with the most compellinε₹g links to disease and advance those prog✔±Ωαrams in tandem.”“Combining our high proficienc§¥©←y in providing custom≈✔πized solutions as early stage druε₹¥g-discovery services, including tailor-m∞ ade biochemical and cell-based assays, with Goα↕₹₹tham’s expertise in e∞¶pitranscriptomics, we were able to establish ✔in a very short time a set of customize←₹₹♥d enzymatic and cellular assays for compou×πnds addressing three different mRNA-modifyin←€∞≤g targets,” said Dr. Sebastian Dempe, Chief§↓✘ Executive Officer of ProQinase. “We lo ↔πok forward to supportinα♠×←g Gotham as the company advances its programs i£γεnto lead optimization and to continueφ₩✘d work with the Gotham team assisting the comλγ↑pany to advance its b¶Ω→road pipeline in a time-effective manner.”In addi §tion to establishing a tailor-made profil↓®ing cascade for compounds from its three m₹α∏ost advanced programs, Go≠♠∏¶tham has also made prδ∞γ✘ogress in strengthenin★λg its drug discovery engine and devel☆₩'∞oping its candidate base₩σ. Gotham previously completed the gene-to<÷ -lead phase for its dr×ug discovery project targeting the METTL3/METTL×14 complex and established a robust discovery p≥↓₽rocess as a platform for future projects. Th• e company has also generated a liπbrary of high-quality compounds tailor-made® for accelerated hit generatio•€¥n and hit-to-lead expansion against large ∞λparts of the epitranscriptomic target space. Th↑₹is library includes a collection of o≥&ver 2,000 analogues covering over 80 distinct ch✘γ emotypes that will be used to≈ ♣ further accelerate Gotham’s drug discov$♥¥"ery efforts as it expands its pipelin®®∏e.The original link:https∑✔<¶://www.pharmafocusasia.c"≠≠om/news/gotham-therapeutics-establishes-adv ∞€←anced-oncology-profiling-cascade-with-p↕Ω'λroqinase-to-progress-its-portfol≠♣↔io-of-epitranscriptomic-drug-candidat ₽±es2019 Asia-pacific pharma IP Leader Summit€✔ ¶: http://en.zenseegroup.com/p/51093™÷ ™4/will be held in Beijing λβ♥↕ on November 14-1γ®♦5, and will attract more∞ than 500 industry experts from do mestic and foreign pharmace¥×πutical companies, biotechnology companies, govern×α•♠ments, associations, law firms, intellectual pro ≥perty agents and other companies to attend.Offi✘Ωcial registration and consultation channels:♥♥αContact：AnnPhone: 021-65650305Email：Mar¶↓↑♠keting@zenseegroup.coΩ ☆δmhttp://en.zenseegroup.com♦γ/p/510934 -
1030
Gilead and Glympse Bio Anno¶↔♣↕unce Strategic Collaboration for Use o∏¶f Biomarker Technology in NASH Cl₹↓λinical Development
Gilead and Glympse Bio Announce Strategic Colσδlaboration for Use of Bi©®omarker Technology in NASH Cβ✘✘®linical DevelopmentTUESDAY, OCTOBER 2±β9, 2019Gilead Sciences Inc. and Glympse Bio, In© ♥c., today announced ×γ₩≤that the companies have entered into a ∑≤♣strategic collaboration in nonalcoholic steato₽λhepatitis (NASH) clinic"∞↔★al development. Glympse Bio’s proprietary synth↕>etic biomarkers – bioengineered to identify st✔↔δage and progression of disea↑®πσse as well as early detection of treatmeα←nt response – will be used to determine¶₹♠ clinical trial participan★↓∏ts’ stage of disease at ∞≥'initial screening and δα≤¶to determine responses to study treatment iσ &n Gilead’s NASH clini♥×≠cal program.“We are excited ab<≈δγout the opportunity to partner with Glymps≠× 'e Bio to help inform our NASH developm₩©>αent program,” said Mani Subramanian, MD, PhD Seni∏ ±✔or Vice President, Liver Diseases, Gilea¶☆♣d Sciences. “By utilizing this↔§ innovative technology, we hope to bett∏≈er characterize this complex disease ©&✔and improve our under∞→ £standing of how our compounds impact d&✘isease progression.”Glympse Bio’s proprietary tec✘¶≤hnology, Glympse Inside™₽∏σ✔, combines synthetic bi∞♠omarkers with machine learning approaches to ideπ∏÷£ntify the stage and monitor progression of impoα¶γ€rtant, complex diseaseλ$s such as cancer, fibrosis, inflammation, a₽α→nd infections, in real time.“We are very ex'¥ε☆cited about partnering with Gilead,&☆ a leader in drug development, to he↕lp drive earlier and more favorable ou∏∞≥'tcomes for patients,” said Caroline J &λLoew, President and CEO, Glympse Bio. “Gileaπ≤©d’s commitment to developing innovative medφ$¶Ωicines in areas of high unmet medical neeα×d aligns with our mission of trα •$ansforming disease detection an•≈ πd measuring treatment response, all with the g<∏☆oal of helping improve the l>↑αives of patients.”information sour§σ¶₹ce:pharma focus AsiaThe'¥φ' original link:https:https:https://www.p≠δ←≈harmafocusasia.com/news/gilea→<✘d-and-glympse-bio-announce-strategic-collaborati ∑☆on-for-use-of-biomarker-technolog↓π↕'y-in-nash-clinical-development2019 Asia-pac¥¶ific pharma IP Leade±±Ω♣r Summit:http://en.zenseegroup.com/p/510934¶®¶↕/ will be held ©↑<in Beijing &nbs♣©≥σp;on November 14-15, and will attr ♦act more than 500 industry experts from dom↔¥$estic and foreign pharmaceutical compani←>es, biotechnology co ™mpanies, governments, associationsδ↕♠←, law firms, intellectual property agδ★₹ents and other companies t ←λ o attend.Official registration and consulta♥₹₩tion channels:Contact：AnnPhone: 02↔₽≥1-65650305Email：Marketing@zenseegroup.comhttp:♥•//en.zenseegroup.com/p/510934 -
1029
HistoIndex Announces ✘♠Global Partnerships To Expa₹€♠εnd AI-Based Digital Pathology Platform
HistoIndex Announces Glo±∏πbal Partnerships To Expand AI-Based Digital ≥Pathology PlatformMONDAY, OCTOBER 28, 2019€HistoIndex announces"α₽ the expansion of its AI-based digital path÷≈♥•ology platform towards large-scale N≤Ω∏ASH preclinical progrβ∞≤ams for pharmaceutic$ al and biotech companies£± ♦ to achieve quantifiable and reproducible d★β←ata on therapeutic responses in NASH ani•"₩↓mal models, and to aid CROs as w"★ell as research agencies in validati↕↕α→ng new models mimicking the NASH dis≈≈♣₹ease.Published preclinicaε®'l studies have demonstrated the use of Hisγ¥toIndex's fully quantifiable Se★§cond Harmonic Generation (SHG) technolog✔↑y as a highly accurate stain-free method that$→ can monitor the efficacy oγ≤₹ f various therapeutic agents, by quantifyin ↑g more than 450 NASH-associated parameter∏s in fibrosis, inflammation, ballooning$∑ and steatosis. The info±λ∞€rmation of these NASH-associated parameters ga↑✔®thered from the entire l♦≤₽€iver tissue, provides compr≈∞♣∑ehensive insights on the mechanism of ±γ₹action of the therapeutic agent. As a d♦δrug discovery tool, HistoIndex's SHG-enabled dig×¥♣ital pathology platform will allow pharmaceutica£¶l and biotech companies to select promising≥¶φ lead candidates for further optimiz✘ ₹ation and make informed decisions in the man €agement of their NASH drug development pipel™←ine.In addition to ongoing NASH cli¥✔£ nical trials, HistoInde•§₹x is currently involved in m§₩ ultiple preclinical st∏•←udies, most of which are conducted by major phar←÷maceutical and biotech &×εcompanies, medical universities, CROs and reΩ£±search agencies. Notably, HistoInd♣βex has recently enteγ✔©red into a collaboration with the A*←&®γSTAR's Genome Institute of Singapore (GIS)₽✘φ to validate their in vivo an✘'d in vitro NASH models based on¶α Asian-centric clinical data. Says Pro<fessor Patrick Tan, Executive Director of ★≠Ω•the Genome Institute¶≤ of Singapore (GIS), "At GIS, we conduct our pr§ ★eclinical studies on fatty liver involvin<g data from animal models based on patient-deriv® ed transcriptomic data. This has a high translβ×<ational potential as it hel₩∑ps us to pinpoint new theraσ↕peutic targets and their va→§ε♥lidation. Therefore, using a fully qua> ntitative, reliable and objective pathological ev $aluation such as HistoIndex's AI-b∞↑∏ased digital pathology platform is ∞•★essential to the success of our efforts in the>∑♦rapeutic target discovery."HistoIndeε∏ε'x is also a partner with globally-renowned CRO,₽$™ WuXi Apptec, in advancing their NASH pr>↕eclinical programs with advanced©'←σ R&D and smart imagin•λ€±g analysis capabilities. Pu∏↓"blished study data will be available for π↑discussions during networking oppo∑↕rtunities throughout AA$₹SLD's The Liver Meeting® in November 2019. § ≈ "We are very excited to extend our≠₹ββ AI-based SHG platform ♥γ≠to preclinical studies to help companies &↕≠with drug discovery programs select pr♣✔εomising lead candidates for further≈☆↕✔ optimization and subsequent c&♥<linical development," says Dr P→¶↔oon Thong Yuen, Chieα ≈f Executive Officer of HistoIndex. ♣∏"Our SHG image analysis platf★•✘orm has already been usedⶮ to analyze the efficacy of a series of promising<φδ drug candidates for NASH within variδ α¶ous animal models commonly-used$☆ by the industry, and we believe t¶≥&hese preclinical partnerships ♥®∑will help drive the adoption of our platfσ©®↔orm significantly."information sou≈• rce:pharma focus AsiaThe original link:https:http♣↑≥s://www.pharmafocusasia.com/news/histoinde±☆∑x-announces-global-partnerships-to-ex₽←pand-ai-based-digital-pat¶εhology-platform2019 Asia-pacific pha☆<rma IP Leader Summit: http://en.zenseegr↔©oup.com/p/510934/will★∞§ be held in Beijing on&nb" ★sp;November 14-15, and will attrac≥α↕t more than 500 industry experts from d€∏omestic and foreign pharmaceutical compa≠≠$nies, biotechnology companies, governmentsβ" , associations, law firms, intellectual property₩©λ agents and other companies to attend.Official &×registration and consultation channe≥♦↕ls:Contact：AnnPhone: 021-λ 65650305Email：Marketing@zenseegroup.co£∑♥∏mhttp://en.zenseegroup.com/p/510934 -
1028
AVROBIO Receives Orphan-Drug Designation fro♦×πm the U.S. FDA for AVR‑RD‑02'≈δ≈ for the Treatment of Gaucher Disease
AVROBIO Receives Orphan-Drug Designatio✘>n from the U.S. FDA for AVR‑RD‑02 for the ≈ →∞Treatment of Gaucher DiseaseFRIDAY, Oσ↑"←CTOBER 25, 2019AVROBIO, Inc., today announce ↓d that the U.S. Food and Drug Administration (F•☆∞DA) has granted orphan-drug designβ€←↕ation for the Company’s inve≠♥stigational gene therapy, AVR-RD-02, for ≤ ←the treatment of Gauc♦☆>her disease. AVR-RD-02 consists of the £ patient’s own hematopoieti≥φφc stem cells, genetically m♥≈odified to express glucocerebrosidase (GCas&Ω€↓e), the enzyme that is deficie€®$nt in Gaucher disease. The Company is actively←®₽ recruiting in Canada for its Phase 1/2 clinica≈Ω≥≈l trial of AVR-RD-02, which seeks to evaluate the$γ× safety and efficacy of the therapy in ε≤<☆patients with Type 1 Gaucher d☆♥isease.“Under the existing stand₹≤ard of care, patients with Gaucher disease are♠≈ bound to a lifelong infusion schedule of enzymγφe replacement therapi♦×βes, and still experience painful and progressiv∞← e symptoms such as debilitating musculos∑←♥keletal pain and fatigue,” s ±aid Birgitte Volck, MD, PhD, Presi®∑&dent of Research and Development at AV₽σπ ROBIO. “Orphan-drug designation recognizes the β≥<≠unmet need of populations with rare di&$seases like Gaucher where AVROBIO strives to t•∏∏$ransform lives by addressing the under≤↓☆lying cause of the disease with a si∑∑✔ngle dose of gene therapy.”Orphan-drug designa↑ γtion is granted by the FDA to drugs and biolπ"Ω'ogics which are intended for↓ the safe and effective₽♠♥ treatment, diagnosis or prevent®λion of rare diseases or cond£itions that affect fewer than 200♥¶,000 people in the United States. Orp£σ'§han-drug designation provλ≤ides certain incentives, which ma£<♦y include tax credits towards the cost♣§ of clinical trials and prescription drug user f$'×ee waivers.information sourcα±←e:pharma focus AsiaThe original link:htt®✘ps:https://www.pharmafocusasia.com/news/av£<× robio-receives-orphan-drug-designation-fro★✔m-the-us-fda-for-avrrd02-for-the-tre§↓atment-of-gaucher-di φsease2019 Asia-pacific pha↑"γ↑rma IP Leader Summit: http://en.zenseegro≠¥☆up.com/p/510934/will be held in Beiji § ng on November 14-15, an≤★ d will attract more than 500 industry exp×≥<erts from domestic and fo"±₽reign pharmaceutical companies, bio★ technology companies, g↑₩γαovernments, associations, l♦®'¶aw firms, intellectual ♣&☆↔property agents and other companies to attend.O♥fficial registration and consultation ←≥channels:Contact：Ann★≈ Phone: 021-65650305Email：M♠™σarketing@zenseegroup.comhttp:/ε ♠✔/en.zenseegroup.com/p/510934 -
1026
AZTherapies Strengthens Neuroinflammation-Tar←®geted Pipeline Through Acquisitiφ€✘on of Smith Therapeutics
FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a ×λbiopharmaceutical company σ☆≠Ωdeveloping therapeutics to extend brain health•λ™↔, today announced theα'®✔ acquisition of Smith Therapγ÷±€eutics, a private biopharmaceutica₽✔÷βl company with a shared goa✘'∞l of targeting neuroinflammation to ♠★treat neurodegenerative disease. S>✘σmith Therapeutics’ Founder and Chief Executive Of×☆→σficer Philip Ashton-Ric&β>δkardt, Ph.D., has joined th×≠×e senior leadership team at AZTherapies as Senior×≤← Vice President of Immunology. Financial te¥¶♣¶rms of the acquisition were not disclosed.Smith T™↕∑←herapeutics’ proprietary resea≥≈ ↓rch platform focuses on the use of mod≥¶ified T cells to res$→≈₽tore a healthy balancα±e of inflammatory and regulator÷∑÷✔y cells in the brain. To date, Smith has success ∏fully engineered immunosuppres↑§sive T regulatory (Treg) cells with Chime♣δαφric Antigen Receptors (CARs→♣) targeting brain glial cells. Previ€↓∑δous research has demonstrated the ab™$♥δility of Tregs to dampλλ↓ en microglial activity and re↓←↔duce neuroinflammation in models o÷©Ω♦f neurodegeneration, suggesting their$£ potential utility in the treatment←≥ of diseases including Progre÷"£ssive Supranuclear Pa•♣lsy (PSP), Alzheimer’s disease, Parkinson’s di♣☆sease, Huntington’s diseaγ<♣se, Amyotrophic Lateral S✔®↔↕clerosis (ALS), and others.“This acquisition repr↔₩esents a meaningful step forward for• ¥λ us as we continue to strengthen our leadersh∞¥ip position in the developme∑"✘'nt of therapies targeting neuro∑€inflammation to stop or sl±↔ow the progression of neurodegenλ£₹erative diseases,” said David R. El≈∑maleh, Ph.D., Founder, CEO, aλ↔nd Chairman of AZTherapies. “We are excited t✘≤o be working with Phσ∑"ilip as we add this cutting-edge teπ☆§chnology to our portfolio '¥of innovative programs. An esteemed immunolog∑☆±"ist and inventor of the <λtechnology, Philip brings u©₩∞Ωnparalleled expertise to the company and ↓←® we look forward to advancing t ∑÷₹his CAR-Treg program further into IND-enablin≠♥g studies and into cl☆εinical development as rapidly as possible.”D©£≥r. Ashton-Rickardt commented on the acquisi↔α≤tion and his appointment: “Our shared₽ ¶ rationale of targeting n÷∞euroinflammation as the root cause of ∏×↓₽neurodegenerative disease makes↔> this acquisition a great strategic fiΩ÷t for us. With AZThera"€pies’ expertise in drug development a≤Ω♠nd clinical trial execution, we believe tha& σt together, we are wel↑₹¶♣l positioned to advance our CAR-Treg technoβ™₩logy and fundamental♦↓ly change neurodegenerativ∞λ"e disease progression.”Prior to launching Smith§♣ Therapeutics in 2017,β≈✔ Dr. Ashton-Rickardt was Chair in Immunology at∞×← Imperial College London ☆★↕, Visiting Professor, Brigham and♠☆∏ Women’s Hospital, Harvard Medical γπSchool, and Associate Profe×δ¶ssor in the Department of Pathology at the U₽'←niversity of Chicago.φ His work has been r∞₩≤ecognized by his peers through the a¥↓©←ward of tenure from The Univer ₹sity of Chicago and by his fellow ci≤ε'↕tizens as a recipient of the Early Career Awardα× for Scientists and EngineersσΩ from President Bill Clinton.$βγ He has published more than 65 peer-reviewed p♥™apers in more than 30 academic journals '✘(including Cell, Science, Immunity, and Natu§παre Immunology), has served a≥δs an editor for several academic joε≥®urnals, and has been a member ♣ £★of grant review boards globally. D×→r. Ashton-Rickardt received a B∑.Sc. in Biochemistry from the University ∑♦λ®of London, King’s College with honors, a P↑←✘h.D. in Molecular Biology from the Universi∞™ty of Edinburgh, and completed post-doctoral wor λδ®k at the University of Edφ¶₩inburgh and the Massachusetts InstΩ $♥itute of Technology in Molecular Biology a"↕λεnd Molecular Immunology, respectively.info→$←rmation source:pharma focus A•λsiaThe original link:https:ht↔•≤tps://www.pharmafocusasia.com/news/≤₹γaztherapies-strengthens-neuroinflammation-tar↓Ωαgeted-pipeline-through-acquisitio☆>n-of-smith-therapeutics2019 As׶•ia-pacific pharma IP Leader Summit™σΩΩ: http://en.zenseegroup.com/p/ ↕510934/will be held in Beijing&n≤™×bsp; on November≥" 14-15, and will attract more than 500 industry ¥δ←experts from domestic and foreign pharmaceutic∞'al companies, biotechnology companies, govern✔•ments, associations, law firms, inγ₩↑↔tellectual property agents and otheλ ♣r companies to attend.Offici★•al registration and consultation φ♣§®channels:Contact：AnnPhone: ±₹021-65650305Email：Marketin∞π♦£g@zenseegroup.comhttp://en.zens€<₽βeegroup.com/p/510934
Contact Us
Zensee_Daystar online
© 2011-2016